Who Owns Pacira Company?

Pacira Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Pacira BioSciences?

Understanding who owns a company is key to grasping its direction and influence. Pacira BioSciences, originally Pacira Pharmaceuticals, Inc., evolved significantly after acquiring MyoScience, Inc. on April 9, 2019.

Founded in 2006 and based in Tampa, Florida, this public pharmaceutical company focuses on non-opioid pain management. Their main product, EXPAREL, aims to reduce post-surgery opioid use.

As a public entity, Pacira BioSciences is owned by its shareholders. The ownership structure includes institutional investors, individual investors, and potentially company insiders. As of March 2025, the company's market capitalization stood at $1.05 billion, reflecting its valuation by the public market. This public ownership means that decisions are influenced by a broad base of stakeholders, all with an interest in the company's performance and strategic growth, including its innovative pain management solutions like those detailed in a Pacira Porter's Five Forces Analysis.

Pacira BioSciences, Inc. was established in 2006. While specific details about the founding team's backgrounds and the initial equity distribution are not extensively documented, the company was previously known as DepoTech and SkyePharma. It operates as a holding company for Pacira Pharmaceuticals, Inc.

Founding Year

Pacira BioSciences, Inc. commenced operations in 2006.

Previous Identities

The company was formerly recognized as DepoTech and SkyePharma.

Corporate Structure

Pacira BioSciences functions as a holding entity for Pacira Pharmaceuticals, Inc.

Early Investment Details

Information regarding early backers, angel investors, or friends and family investments during the initial phase is not readily available.

Initial Agreements

Details on early agreements such as vesting schedules, buy-sell clauses, or founder exits are not specified.

Founding Vision and Control

The extent to which the founding team's vision influenced the initial distribution of control cannot be fully detailed based on available information.

While the precise identities of all founders and their initial equity stakes are not publicly detailed, the company's history includes operating under the names DepoTech and SkyePharma before becoming Pacira BioSciences, Inc. in 2006. As a holding company for Pacira Pharmaceuticals, Inc., its early ownership structure, including any initial agreements or potential disputes, remains largely undocumented in the provided information. Understanding the Revenue Streams & Business Model of Pacira can offer further context to its early development.

Key Ownership Aspects

Information regarding the initial ownership structure of Pacira BioSciences, including early investors and founder agreements, is not extensively detailed.

• Founded in 2006.
• Previously known as DepoTech and SkyePharma.
• Operates as a holding company for Pacira Pharmaceuticals, Inc.
• Specifics on early equity splits and founder exits are not publicly available.

Pacira SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Pacira BioSciences, Inc. is a publicly traded entity, and its ownership structure has seen notable shifts, particularly with recent strategic acquisitions. The company's journey reflects a dynamic interplay between institutional investment and targeted growth initiatives.

The ownership landscape of Pacira BioSciences, Inc. is heavily influenced by institutional investors, who collectively hold a significant stake. This high level of institutional backing often signals confidence in the company's long-term strategy and financial stability. Key players among these institutional shareholders include Vanguard Fiduciary Trust Co. and D.E. Shaw & Co., Inc., alongside State Street Corp., which holds 4.29% of the shares. This concentration of ownership among large financial institutions suggests a focus on growth and market expansion, aligning with the company's stated objectives.

Key Stakeholders and Strategic Moves

Pacira BioSciences' ownership is characterized by substantial institutional investment and strategic acquisitions aimed at bolstering its product pipeline.

• Institutional ownership exceeds 100%, indicating significant investment activity.
• Vanguard Fiduciary Trust Co. and D.E. Shaw & Co., Inc. are major institutional shareholders.
• State Street Corp. holds 4.29% of the company's shares.
• In February 2025, Pacira acquired 81% of GQ Bio Therapeutics GmbH for $32 million, enhancing its genetic medicine platform.
• This acquisition supports Pacira's '5x30' growth strategy.
• Understanding these ownership dynamics is crucial for assessing the company's strategic direction and Mission, Vision & Core Values of Pacira.

Pacira PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of July 2025, the board of directors for Pacira BioSciences comprises nine members, including CEO Frank D. Lee and Independent Board Chair Laura Brege. The board saw a reduction in size from twelve to nine members following the resignations of Paul Hastings and Andreas Wicki, with Laura Brege stepping into the Chair role on January 28, 2025.

In a move to bolster corporate governance, Pacira BioSciences implemented a majority voting standard in March 2025 for director elections in uncontested scenarios; directors now require more favorable votes than against to secure their position. This standard contrasts with the plurality vote standard maintained for contested elections. The company's 2024 proxy statement details director and executive officer interests in Pacira by security holdings. As of June 10, 2025, there were 46,290,830 outstanding shares of common stock eligible to vote at the Annual Meeting. Earlier in March 2025, DOMA Perpetual Capital Management LLC put forward three nominees for the Board of Directors at the 2025 Annual Meeting, a proposal under the company's Board and management evaluation.

Understanding Pacira BioSciences' Shareholder Landscape

Pacira BioSciences' ownership structure is influenced by its public trading status and the voting power of its shareholders. Understanding who owns Pacira BioSciences is key to grasping its corporate direction.

• The company is publicly traded, making its stock accessible to a wide range of Pacira BioSciences investors.
• Institutional investors often hold significant stakes, influencing Pacira BioSciences' financial performance.
• Shareholder activism, as seen with nominations for the board, can impact company strategy.
• Information on Pacira BioSciences SEC filings ownership provides detailed insights into major shareholders.
• The Marketing Strategy of Pacira is often shaped by its investor base.

Pacira Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments at Pacira BioSciences have significantly shaped its ownership landscape, with strategic acquisitions and capital management initiatives influencing its shareholder base. The company's focus on growth and efficiency is a key driver for its investors.

Pacira BioSciences has been actively managing its capital structure and pursuing strategic growth opportunities. These actions are designed to enhance shareholder value and position the company for future success. The company's commitment to innovation, as seen in its acquisition strategy, is a key factor for its current and potential Pacira BioSciences investors.

Shareholder Value Enhancement

The company authorized a substantial share repurchase program of up to $300 million in April 2025. This move signals management's confidence and aims to boost Pacira BioSciences stock value for its shareholders.

Strategic Pipeline Expansion

The acquisition of GQ Bio Therapeutics GmbH in February 2025 for $32 million integrates a novel gene therapy platform. This aligns with Pacira's '5x30' growth strategy, aiming to advance its innovative pipeline and attract investors focused on biotech advancements.

Operational Efficiency Focus

A workforce reduction of approximately 8% was implemented in September 2025, following manufacturing improvements. This is expected to yield annual operating expense savings of around $13 million, positively impacting Pacira BioSciences financial performance.

Leadership and Collaboration

The appointment of Frank D. Lee as CEO in January 2024 and a strategic collaboration with Johnson & Johnson MedTech in July 2025 highlight leadership changes and expanded market reach. These developments are crucial for understanding who owns Pacira BioSciences and its future direction.

Pacira Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔